Ricardo Gonzalez, MD
Urology · Houston, TXNPI 1629020292
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 77.2% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2019 at $140,914 and has fallen 97.2% since, to $3,911 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 496 payments — averaging $632.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$242K
- Procept Biorobotics Corporation$56K
- AbbVie$8K
- Medtronic$3K
- Coloplast$1K
- Angiodynamics, Inc.$484
- plus $3K from 30 others
Across 4 payments — averaging $7555.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Laborie Medical Technologies Corp.$27K
- Boston Scientific$3K
What the payments were for
- Consulting fees$66,13221%
- Speaking & faculty fees$185,59559%
- Grants$900%
- Travel & lodging$43,97214%
- Food & beverage$17,8146%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 190 | $242,312 |
| Procept Biorobotics Corporation | 84 | $56,036 |
| AbbVie(2 entities) | 57 | $7,925 |
| Medtronic(3 entities) | 46 | $3,194 |
| Coloplast | 17 | $1,058 |
| Angiodynamics, Inc. | 8 | $484 |
| Axonics, Inc. | 14 | $447 |
| Olympus America Inc. | 7 | $341 |
| Astellas Pharma US Inc | 14 | $293 |
| Johnson & Johnson | 5 | $174 |
| Endo USA, Inc. | 2 | $164 |
| Teleflex LLC | 2 | $160 |
| Pfizer | 9 | $140 |
| I/o Urology Corp. | 1 | $117 |
| Urogen Pharma, Inc. | 1 | $108 |
| Terumo Medical Corporation | 1 | $107 |
| 180 Medical, Inc. | 5 | $93 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Convatec Inc. | 2 | $68 |
| Baxter Healthcare | 1 | $61 |
| Neotract Inc. | 1 | $61 |
| Antares Pharma, Inc. | 3 | $48 |
| Ambu Inc. | 4 | $44 |
| Novo Nordisk | 2 | $44 |
| Myriad Genetic Laboratories, Inc. | 2 | $39 |
| Endo Pharmaceuticals Inc. | 2 | $35 |
| Laborie Medical Technologies Corp. | 3 | $29 |
| Hollister Incorporated | 2 | $29 |
| ABC Home Medical Supply, Inc. | 1 | $23 |
| Alafair Biosciences, Inc. | 1 | $22 |
| Dentsply IH Inc. | 1 | $20 |
| Duchesnay USA Incorporated | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GREENLIGHT$95,914
- AquaBeam Robotic System$54,607
- REZUM$38,405
- GENERAL - THERAPIES$28,908
- GENERAL BPH$17,931
- BOTOX$7,041
- GreenLight XPS$5,724
- GENERAL PELVIC ORGAN PROLAPSE$3,600
- XENFORM$2,475
- INTERSTIM$2,253
- rezum Generator$1,350
- Solyx SIS System$687
- Advantage System$500
- AQUABEAM SYSTEM$329
- GENERAL FEMALE SUI$235
- TACTRA$148
- XIAFLEX$146
- ALTIS$144
- UroLift System$142
- Axonics$142
How this compares
$313,820 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 230 | $154,739 |
| GemtesaVibegron | 83 | $71,658 |
| Silodosin | 203 | $20,636 |
| Dutasteride | 469 | $17,098 |
| Mirabegron ErMirabegron | 22 | $13,932 |
| Solifenacin Succinate | 169 | $10,183 |
| Tamsulosin Hcl | 490 | $9,481 |
| Finasteride | 385 | $6,126 |
| Methenamine Hippurate | 80 | $5,840 |
| Estradiol | 86 | $5,814 |
| Trospium Chloride | 100 | $5,517 |
| Fosfomycin Tromethamine | 14 | $4,198 |
| Desmopressin Acetate | 61 | $2,804 |
| Tadalafil | 25 | $2,744 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 125 | $2,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $293 | $154,739230 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $71 | $71,65883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 urology providers in Texas.
Other urology in Houston
- Arun RaiHouston$920K
- Donald GriffithHouston$732K
- Jonathan Clavell HernandezHouston$500K
- Ashish KamatHouston$481K
- Mohit KheraHouston$428K
- Richard LinkHouston$261K
- Steven CanfieldHouston$256K
- Run WangHouston$195K
- Kathleen KobashiHouston$159K
- Steven MaislosHouston$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.